3439.60
4.17%
Karvy
Revenues for the quarter at Rs 7039 mn were below our estimates of Rs7760mn. The margins were in-line with our estimate and stood at 20% inQ3FY18 as against 7.4% in Q3FY17. Higher margins were mainly onaccount of better gross margins.
GlaxoSmithKline Pharmaceuticals Ltd. has gained 21.25% in the last 3 Months
More from GlaxoSmithKline Pharmaceuticals Ltd.
Recommended